Eclipseregenesis
Founded 2017 · 8 employees on LinkedIn · 1 known investors
Find your way into Eclipseregenesis
154 people in our graph share verified history with the Eclipseregenesis team — schools, employers, funds. One of them is your warm intro.
Eclipse Regenesis develops a regenerative therapy platform for treating intestinal failure, starting with Short Bowel Syndrome, and extending to other complex gastrointestinal conditions. The company is a medical device developer focused on enabling the body's own tissue to rebuild rather than relying on invasive replacements.
Founders & leadership
Eclipseregenesis was founded in 2017 by Andre Bessette, James Dunn, and Tom Krummel.
Investors · 1
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2023 | $970.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $423.2K |
| National Science Foundation | Phase I | 2021 | $256K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Eclipseregenesis do?
- Eclipse Regenesis develops a regenerative therapy platform for treating intestinal failure, starting with Short Bowel Syndrome, and extending to other complex gastrointestinal conditions. The company is a medical device developer focused on enabling the body's own tissue to rebuild rather than relying on invasive replacements.
- Who founded Eclipseregenesis?
- Eclipseregenesis was founded by Andre Bessette, James Dunn, Tom Krummel in 2017.
- Who are Eclipseregenesis's investors?
- Eclipseregenesis's investors include Atacama Ventures.